Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Immunoexpression of BAP1, ROS1, and ALK in Spitzoid Melanocytic Tumors

Texto completo
Autor(es):
Cardili, Leonardo [1, 2] ; Viana, Cristiano Ribeiro [3] ; Germano, Andressa [1] ; Fernandes, Mariana [1] ; Barcellos, Denise [1] ; Landman, Gilles [1]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Fed Sao Paulo, Sao Paulo - Brazil
[2] Inst Canc Estado Sao Paulo, Sao Paulo - Brazil
[3] Hosp Canc Barretos, Fundacao Pio 12, Barretos - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY; v. 26, n. 6, p. 514-520, SEP 2018.
Citações Web of Science: 0
Resumo

Background. Spitzoid tumors are a heterogeneous group of melanocytic neoplasms that frequently imposes diagnostic difficulties. Lately, several advances in molecular biology afforded significant discoveries on the pathogenesis of these tumors. BAP1 (BRCA-1 associated protein-1) inactivation and anomalous expression of kinase translocation-related proteins are among the main criteria launched by new classification proposals. Our aim was to systematically assess the immunoexpression of BAP1, ROS1 (receptor tyrosine kinase c-Ros oncogene 1), and ALK (anaplastic lymphoma receptor tyrosine kinase) proteins in an unpublished series of spitzoid tumors. Methods. Retrospective study based on 47 formalin-fixed paraffin-embedded tissue samples from 3 different institutions. BAP1, ROS1, and ALK immunostains were performed in all cases. We included 27 Spitz tumors without significant abnormality, 15 atypical spitzoid tumors, and 5 spitzoid melanomas. Results. We observed loss of BAP1 nuclear immunolabeling in 4.3% of evaluable cases (2/46), both of them atypical spitzoid tumors. The proportional frequency of BAP1-inactivated cases among atypical spitzoid tumors was 14.2% (2/14). No immunoexpression of ROS1 or ALK was found. Conclusions. Our study revealed 2 additional BAP1-inactived cases and described its respective frequency. The absence of anomalous expression of translocation-related proteins ALK and ROS1 in this series, composed predominantly of low-grade/low-risk tumors, indicates that translocated spitzoid lesions may not be as prevalent as initially suggested, at least in some populations. Furthermore, our findings encourage additional investigation on unequal occurrence of such immunomarkers among different diagnostic categories of spitzoid neoplasms. (AU)

Processo FAPESP: 14/21860-0 - Síndrome de Lynch: deleções do gene EPCAM e das mutações germinativas em tumores de pacientes brasileiros
Beneficiário:Celina Tizuko Fujiyama Oshima
Linha de fomento: Auxílio à Pesquisa - Regular